Drug Profile
OMO 2
Alternative Names: DO-2; OMO-2Latest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Developer DeuterOncology
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-met inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Nov 2023 DeuterOncology plans a phase II trial for solid tumours (DeuterOncology pipeline, November 2023)
- 20 Dec 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, First-line therapy) in Netherlands, Belgium (PO) (NCT05752552) (EudraCT 2022-001681-35)
- 30 Nov 2022 OMO 2 licensed to DeuterOncology worldwide excluding greater China (DeuterOncology pipeline, March 2023)